Drug Trial Radar · NCT07342868
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jan 30, 2026
Primary completion
Aug 19, 2026
Study completion Aug 19, 2026
Sponsor
- Lead sponsor
- Aligos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).
Conditions
- Chronic Hepatitis B Infections
Interventions
Pevifoscorvir Sodium (ALG-000184)Drug
Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration time curve [AUC]Time frame: Up to 4 days
- Time to maximum plasma concentration [Tmax]Time frame: Update to 4 Days
- Maximum plasma concentration [Cmax]Time frame: Update to 4 days
- Minimum plasma concentration [Cmin]Time frame: Up to 4 days
- C0 (predose)Time frame: Up to 4 days
- Half-life [t1/2]Time frame: Up to 4 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Orlando Clinical Research Center
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.